Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

Shibo Jiang, Maria Elena Bottazzi, Lanying Du, Sara Lustigman, Chien Te Kent Tseng, Elena Curti, Kathryn Jones, Bin Zhan, Peter J. Hotez

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.

Original languageEnglish (US)
Pages (from-to)1405-1413
Number of pages9
JournalExpert review of vaccines
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2012

    Fingerprint

Keywords

  • SARS
  • receptor-binding domain
  • recombinant vaccine
  • severe acute respiratory syndrome
  • spike (S) protein

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this